	US 12,077,600 B2
	Anti-thymidine kinase antibodies
Hartmut Duefel, Penzberg (DE); Alfred Engel, Penzberg (DE); Frank Kroner, Penzberg (DE); Thomas Meier, Penzberg (DE); Sandra Rutz, Penzberg (DE); Michael Schraeml, Penzberg (DE); Gloria Tabares, Penzberg (DE); Ulrike Kurtkaya, Penzberg (DE); Boris Pinchuk, Penzberg (DE); and Christina Zimmermann, Penzberg (DE)
Assigned to Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed by Roche Diagnostics Operations, Inc., Indianapolis, IN (US)
Filed on Oct. 13, 2020, as Appl. No. 17/069,349.
Application 17/069,349 is a continuation of application No. PCT/EP2019/059775, filed on Apr. 16, 2019.
Claims priority of application No. 18168009 (EP), filed on Apr. 18, 2018.
Prior Publication US 2021/0061924 A1, Mar. 4, 2021
Int. Cl. G01N 31/00 (2006.01); C07K 16/40 (2006.01); G01N 33/53 (2006.01); G01N 33/543 (2006.01)

CPC C07K 16/40 (2013.01) [G01N 33/54326 (2013.01); C07K 2317/92 (2013.01)]

19 Claims

1. A monoclonal antibody that specifically binds to human thymidine kinase 1 (hTK-1; SEQ ID NO:1) the antibody being characterized in that it

a) binds to a conformation dependent epitope of hTK-1,

b) does not bind to a polypeptide consisting of amino acids 194 through 225 of hTK-1 (SEQ ID NO:2), and

c) does not bind to any polypeptide consisting of 15 consecutive amino acids of hTK-1.